In recent years, HER2-targeted antibody-drug conjugates (ADCs): trastuzumab deruxtecan (T-DXd) and trastuzumab duocarmazine (SYD985) have shown promising anti-tumor activity in patients with HER2-low BC [45, 46]. Here, ERBB2 is linked to breast cancer.